

Discontinuation of Rasilez HCT in Europe and Switzerland

Noden Pharma has made a business decision to permanently discontinue Rasilez HCT in Europe and Switzerland for commercial reasons.

Noden Pharma will continue to supply Rasilez 150mg and Rasilez 300mg to the market.

For any countries where certain HCT strengths are discontinued, patients can take Rasilez 150mg and 300mg (which can be co-administered with a separate hydrochlorothiazide tablet from a different MAH).

Detailed below is the latest status of Rasilez HCT discontinuation

Availability of Rasilez HCT				
	Rasilez HCT 150/12.5mg	Rasilez HCT 150/25mg	Rasilez HCT 300/12.5mg	Rasilez HCT 300/25mg
Austria	✗	✓	✓	✗
Ireland	✗	✗	✗	✗
Germany	✓	✓	✓	✓
Spain	✗	✓	✓	✓
Italy	✗	✗	✓	✓
Switzerland	✗	✓	✓	✓
Netherlands	✓	✓	✗	✗



Product strength available at wholesale level.

Product strength no longer available at wholesale level.

 **Rasilez HCT®**

film-coated tablets
aliskiren/hydrochlorothiazide

NODEN  **PHARMA™**